Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

24 terminated/withdrawn out of 120 trials

Success Rate

78.8%

-7.8% vs industry average

Late-Stage Pipeline

16%

19 trials in Phase 3/4

Results Transparency

44%

39 of 89 completed trials have results

Key Signals

2 recruiting39 with results19 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 1
67(58.3%)
Phase 2
23(20.0%)
Phase 3
16(13.9%)
N/A
6(5.2%)
Phase 4
3(2.6%)
115Total
Phase 1(67)
Phase 2(23)
Phase 3(16)
N/A(6)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (120)

Showing 20 of 120 trials
NCT03310632Phase 1Completed

Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

Role: collaborator

NCT04880109Phase 2Terminated

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

Role: collaborator

NCT04604782Phase 1Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Role: collaborator

NCT00874237Phase 1Completed

Staccato Loxapine Thorough QT/QTc Study

Role: collaborator

NCT07247942Phase 1Completed

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

Role: collaborator

NCT04606537Phase 1Completed

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Role: collaborator

NCT04634812Phase 1Completed

Mass Balance Study of KBP-5074 in Healthy Male Subjects

Role: collaborator

NCT04534699Phase 1Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Role: collaborator

NCT04116658Phase 1Completed

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

Role: collaborator

NCT01992952Phase 1Active Not Recruiting

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Role: collaborator

NCT04412616Phase 1Recruiting

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

Role: collaborator

NCT04008186Phase 1Completed

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Role: collaborator

NCT03673111Phase 1Completed

Study of the Gut Hormone Analogue Y14 in Adult Subjects

Role: collaborator

NCT03714815Phase 2Terminated

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Role: collaborator

NCT05664672Not ApplicableCompleted

Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches

Role: collaborator

NCT03102606Phase 3Completed

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Role: collaborator

NCT03402841Phase 3Completed

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Role: collaborator

NCT04691115Phase 1Completed

Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects

Role: collaborator

NCT01744704Phase 1Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Role: collaborator

NCT05121948Phase 1Terminated

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Role: collaborator